Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: J Stroke Cerebrovasc Dis. 2022 Aug 30;31(10):106724. doi: 10.1016/j.jstrokecerebrovasdis.2022.106724

Table 2:

Summary of outcome measures recorded at each testing session (Mean ± 95% CI) as compared to baseline.

Outcome Measure Cyproheptadine Placebo
Baseline Intent-to-treat Paired Sample Statistics Baseline Intent-to-treat Paired Sample Statistics Session * Group Effect
Grip Termination Time (Sec) 5.48 ± 1.41 2.65 ± 1.09 p<0.001* 5.63 ± 1.85 4.71 ± 1.67 p=0.371 p = 0.042*
CMSA-H
Score 2		 8.63 ± 3.75 3.77 ± 3.07 p=0.023 6.57 ± 3.60 6.72 ± 3.28 p=0.932 p=0.063
CMSA-H
Score 3		 4.30 ± 1.15 2.23 ± 0.97 p=0.004 4.99 ± 1.96 3.37 ± 1.59 p=0.204 p=0.741
MCP Flexion MVC (Nm) 2.34 ± 0.4 2.31 ± 0.44 p=0.672 1.94 ± 0.64 2.12 ± 0.44 p=0.406 p = 0.569
Residual Grip Strength (Paretic Grip/Non-paretic Grip) 0.13 ± 0.03 0.10 ± 0.03 p=0.029 0.12 ± 0.03 0.12 ± 0.03 p=0.679 p = 0.234
MCP Reflex Torque (Nm) 0.66 ± 0.14 0.31 ± 0.06 p=0.190 0.88 ± 0.18 0.80 ± 0.19 p=0.187 p = 0.600
FDS Coactivation during Extension (%) 0.31 ± 0.06 0.24 ± 0.05 p=0.050 0.30 ± 0.07 0.24 ± 0.05 p=0.115 p = 0.530
ESS (score) 5.5 ± 1.0 5.74 ± 1.41 p=0.824 7.6 ± 1.39 5.27 ± 1.47 p<0.001* p = 0.002*
BDI-II (score) 7.45 ± 2.05 6.36 ± 1.81 p=0.249 7.67 ± 1.97 4.72 ± 1.46 p<0.001 p = 0.441

Asterisk in the Session * Group Effect column indicates a significant effect of the interaction. Paired sample statistics are marked as significant if p<0.05 and the Session * Group interaction was also significant.